Abstract
About this talk
Background: Vernal keratoconjunctivitis (VKC) is a chronic, bilateral allergic inflammation of the ocular surface. It combines an IgE-mediated reaction with a T-helper-2-driven inflammatory component, and it mainly affects boys and young adolescents in warm, dry climates. Diagnosis is usually straightforward, but disease control is difficult. Prolonged topical corticosteroid use exposes patients to cataract, glaucoma and infection. Severe forms can progress through superficial punctate keratitis, epithelial macroerosions and shield ulcers to limbal stem cell deficiency (LSCD), with corneal conjunctivalisation, persistent pannus and irreversible visual loss.
Case presentation: A 16-year-old boy with no reported personal or family history of atopy was referred for a two-year history of progressive bilateral red eye and decreased vision. Best-corrected visual acuity was 1/10 in the right eye and 5/10 in the left eye. Both eyes showed diffuse conjunctival hyperaemia, giant tarsal papillae (palpebral VKC) and a 360° corneal pannus. In the right eye, the pannus reached the visual axis with neovascularisation, and the fundus was not visible because of media opacity. The left eye also had an inferior corneal ulcer. Allergological work-up confirmed an atopic profile, with a positive histamine skin test.
Initial treatment consisted of ocular lavage, topical antihistamines, mast-cell stabilisers and vitamin A ointment. Symptoms improved slightly and the ulcer healed, but the pannus remained unchanged. A subtarsal injection of long-acting corticosteroid did not change the corneal appearance. A conjunctival biopsy then excluded other causes of chronic cicatrising conjunctivitis, and topical cyclosporine 2% was started. This produced partial regression of corneal conjunctivalisation and pannus. However, burning and ocular discomfort on instillation limited sustained use of the drug.
Discussion: Corneal complications, including LSCD with vascularised pannus, are not uncommon in severe VKC and represent the main threat to vision. The patient’s bilateral 360° pannus reaching the visual axis, together with the ulcer in the fellow eye, corresponds to the most severe end of the Gokhale and Bonini grading systems. Topical cyclosporine, a calcineurin inhibitor, is the principal corticosteroid-sparing agent, and tacrolimus is an alternative. For refractory disease, further options include systemic immunomodulators, surgical measures (papillae excision, superficial or phototherapeutic keratectomy, amniotic membrane transplantation) and biologic agents such as omalizumab, which can achieve sustained remission.
Conclusion: VKC can evolve into severe, bilateral, vision-threatening limbal stem cell deficiency in young patients. Topical cyclosporine is valuable, but its efficacy and tolerability may be insufficient in the most severe cases. A structured, severity-based therapeutic ladder and early recognition of treatment-resistant disease, including early consideration of biologic therapy, are essential to preserve the ocular surface and visual function.
Speaker
About the speaker

